IRD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Opus Genetics Inc (IRD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including hedge fund interest, analyst ratings with high price targets, and recent financing to support its gene therapy programs. Despite some financial challenges, the company is in a growth-oriented phase, and technical indicators suggest bullish momentum.
The MACD histogram is positive at 0.0832, indicating bullish momentum, though it is contracting. RSI is neutral at 61.53, and moving averages show a bullish trend (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 3.862 and 4.276, with support at 2.521 and 2.107.
The company has secured $25 million in financing to advance its gene therapy programs, which address high unmet medical needs.
The company's financials show a decline in revenue (-20.38% YoY) and EPS (-13.79% YoY). The stock has a 40% chance of a slight decline (-0.64%) in the next day and mixed short-term performance probabilities.
In Q3 2025, revenue dropped by 20.38% YoY to $3,079,000. Net income improved significantly by 131.92% YoY to -$17,454,000, indicating better cost management. EPS declined to -0.25 (-13.79% YoY). The gross margin remained strong at 100%.
Analysts from LifeSci Capital, B. Riley, and Piper Sandler have initiated coverage with 'Outperform', 'Buy', and 'Overweight' ratings, respectively. Price targets range from $7 to $9, indicating significant upside potential from the current price of $3.67.
